ArticleJournal of neuro-oncology2011
Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma.
Article in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies.AJNR. American journal of neuroradiology · 2020Trial
- Diffuse Midline Gliomas: Clinical, Diagnostic, and Therapeutic Perspectives.Biomedicines · 2026Review
- Prognostic role of delta radiomics in pediatric pontine diffuse midline gliomas.Journal of neuro-oncology · 2026Article
- Applications of artificial intelligence and advanced imaging in pediatric diffuse midline glioma.Neuro-oncology · 2025Review
- Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC.Neuro-oncology · 2024Article
- Article
- Article
- Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle.Diagnostics (Basel, Switzerland) · 2022Review
- Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.Medical physics · 2021Article
- MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry.Neuro-oncology · 2020Article
- Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas.Biomolecules · 2020Review
- Correlation of multimodalTheranostics · 2020Article
- Magnetic resonance spectroscopic imaging in gliomas: clinical diagnosis and radiotherapy planning.BJR open · 2020Review
- Assessment of Overall Survival in Glioma Patients as Predicted by Metabolomic Criteria.Frontiers in oncology · 2019Article
- Direct Involvement of Cranial Nerve V at Diagnosis in Patients With Diffuse Intrinsic Pontine Glioma: A Potential Magnetic Resonance Predictor of Short-Term Survival.Frontiers in oncology · 2019Article
- Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?Neuro-oncology · 2017Review
- Progressive multifocal exophytic pontine glioblastoma: a case report with literature review.Chinese journal of cancer · 2017Review
- Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma.Current neuropharmacology · 2017Review
- Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism.Journal of child neurology · 2016Review
- Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies.Neuroradiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Patients with diffuse intrinsic pontine glioma (DIPG) face a grim prognosis with limited treatment options. Many patients will enroll on investigational trials though the role of chemotherapy or immunotherapy is unclear. Radiographic changes on conventional MRI are used to evaluate tumor response and progression, but are not predictive of outcome in these patients. More sensitive measures of tumor biology are needed to improve patient management. We evaluated changes in magnetic resonance spectroscopy (MRS) biomarkers in patients with DIPG. Thirty-eight patients were enrolled prospectively on an IRB-approved protocol, which included standard MRI, single voxel spectroscopy (SVS) and multi-slice multi-voxel spectroscopy (MRSI). Scans were performed at multiple time points during each patient's clinical course, with a total of 142 scans. The prognostic values of Choline:N-acetylaspartate (Cho:NAA), Cho:Creatine (Cho:Cr) and the presence of lactate and lipids (+Lac/Lip) were evaluated. Cho:NAA and variance in Cho:NAA values among different voxels within a tumor were each predictive of shorter survival. This prospective study shows that MRS can be used to identify high-risk patients and monitor changes in tumor metabolism, which may reflect changes in tumor behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.